Filing Flows › Comparisons › CTOR vs ROIV
Citius Oncology vs Roivant Sciences: CTOR and ROIV compared
Citius Oncology is the larger company: $1.5M of revenue in its latest quarter (Q3 FY26) against $1.4M for Roivant Sciences (Q1 FY27).
Where the money goes: CTOR and ROIV
Citius Oncology (CTOR) · Q3 FY26
Citius Oncology, Q3 FY26: revenue $1.5M, operating margin -583.5%, net loss $8.9M, operating cash flow −$2.7M. The chart follows the revenue to costs, profit and cash.
Roivant Sciences (ROIV) · Q1 FY27
Roivant Sciences, Q1 FY27: revenue $1.4M (-34% year over year), net loss $291M, operating cash flow −$271M. The chart follows the revenue to costs, profit and cash.
| Citius Oncology (CTOR) | Roivant Sciences (ROIV) | |
|---|---|---|
| Latest quarter | Q3 FY26 | Q1 FY27 |
| Revenue | $1.5M | $1.4M |
| Revenue growth, Y/Y | — | -34% |
| Operating margin | -583.5% | n/m |
| Net earnings | −$8.9M | −$291M |
| Net margin | -597.4% | — |
| Operating cash flow | −$2.7M | −$271M |
Questions
Which is bigger, Citius Oncology or Roivant Sciences?
Citius Oncology is the larger company: $1.5M of revenue in its latest quarter (Q3 FY26) against $1.4M for Roivant Sciences (Q1 FY27).
More: Citius Oncology earnings · how Citius Oncology makes money · Roivant Sciences earnings · how Roivant Sciences makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 14, 2026; 10-Q filed Aug 6, 2026). Fiscal quarters can end on different dates. Not investment advice.